← All trials
NCT05219721
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 17, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Mar 1, 2024
- First posted
- Feb 2, 2022
- Last posted
- May 24, 2022
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- IASO Pharma Inc.Collaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.